Assess whether to drop a secondary endpoint that will dominate the AdCom

SITUATION Phase-3 protocol with endpoint-sensitivity issues arrived with a boxed-warning proposal from the review division for pediatric-plan strategist. That is a Pharma & Life Sciences Clinical and Evidence Strategy decision on to drop a secondary in a 505(b)(2) program relying on literature plus a bridging study.

DECISION Pediatric-plan strategist in a 505(b)(2) program relying on literature plus a bridging study must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using phase-3 protocol with endpoint-sensitivity issues after a boxed-warning proposal from the review division.

HYPOTHESES TO TEST 1. Pediatric-plan strategist can defend Proceed under protocol from phase-3 protocol with endpoint-sensitivity issues after a boxed-warning proposal from the review division in a Pharma & Life Sciences challenge. 2. Pediatric-plan strategist cannot defend Proceed under protocol from phase-3 protocol with endpoint-sensitivity issues; Pause the pathway is what the extract actually supports after a boxed-warning proposal from the review division. 3. A boxed-warning proposal from the review division never reached the population in phase-3 protocol with endpoint-sensitivity issues — reopen intake, do not close to drop a secondary. 4. Two facts in phase-3 protocol with endpoint-sensitivity issues after a boxed-warning proposal from the review division conflict for pediatric-plan strategist; hold this Clinical and Evidence Strategy file.

ANALYSIS REQUIRED 1. Trace CMC, labeling, or pharmacovigilance facts in phase-3 protocol with endpoint-sensitivity issues after a boxed-warning proposal from the review division. 2. Separate an isolated adverse event from a systemic quality issue. 3. Test a protocol deviation versus a safety signal versus a filing gap on to drop a secondary. 4. For this Pharma & Life Sciences Clinical and Evidence Strategy file, read phase-3 protocol with endpoint-sensitivity issues against a boxed-warning proposal from the review division and write the one fact that would move to drop a secondary for pediatric-plan strategist.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / Clinical and Evidence Strategy packet (phase-3 protocol with endpoint-sensitivity issues after a boxed-warning proposal from the review division). Lead with the Pharma & Life Sciences option phase-3 protocol with endpoint-sensitivity issues can support after a boxed-warning proposal from the review division, then the two facts that force it, then the Monday action for pediatric-plan strategist in a 505(b)(2) program relying on literature plus a bridging study.